Currently out of the existing stock ratings of Alethia Young, 255 are a BUY (79.19%), 60 are a HOLD (18.63%), 7 are a SELL (2.17%).

Alethia Young

Work Performance Price Targets & Ratings Chart

Analyst Alethia Young, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 60.96% that have a potential upside of 51.01% achieved within 367 days.

Alethia Young’s has documented 620 price targets and ratings displayed on 54 stocks. The coverage is on Healthcare, Basic Materials sectors.

Most recent stock forecast was given on RCUS, Arcus Biosciences at 05-Jul-2024.

Wall Street Analyst Alethia Young

Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for BIIB (BIOGEN) at 11/3/2020. The price target of $278 was fulfilled within 1 day with a profit of $30.99 (12.55%) receiving and performance score of 125.46.

Average potential price target upside

of $104 (170.57%) on CRIS (CURIS).
of $87.63 (51.58%) on ICPT (INTERCEPT PHARMACEUTICALS).
of $77.17 (16.82%) on REGN (REGENERON PHARMACEUTICALS).

ACHN Achillion Pharmaceuticals ADVM Adverum Biotechnologies AGIO Agios Pharm ALNY Alnylam Pharmaceuticals AMGN Amgen ARNA Arena Pharmaceuticals ARWR Arrowhead Pharmaceuticals ASND Ascendis Pharma AS BIIB Biogen FATE Fate Therapeutics GILD Gilead Sciences ICPT Intercept Pharmaceuticals INCY yte PBYI Puma Biotechnology PTCT PTC Therapeutics RAPT RAPT Therapeutics REGN Regeneron Pharmaceuticals SPPI Spectrum Pharmaceuticals SRPT Sarepta Therapeutics TGTX TG Therapeutics VRTX Vertex Pharmaceuticals BMRN Biomarin Pharmaceutical AA Alcoa Corp AKBA Akebia Ther ALXN Alexion Pharmaceuticals ARVN Arvinas AUPH Aurinia Pharmaceuticals CELG Celgene CLF Cleveland-Cliffs CRIS Curis FCX Freeport-McMoran Copper & Gold GBT Global Blood Therapeutics MYOK MyoKardia PRVB Provention Bio ELDN Eledon Pharmaceuticals UTHR United Therapeutics CLVS Clovis Oncology NKTX Nkarta NEXI Neximmune MRNS Marinus Pharmaceuticals STML Stemline Therapeutics STOK Stoke Therapeutics THRX Theseus Pharmaceuticals VSTM Verastem LBPH Longboard Pharmaceuticals ALXO Alx Oncology Holdings RCUS Arcus Biosciences BCYC Bicycle Therapeutics Ltd CHRS Coherus BioSciences IONS Ionis Pharmaceuticals MESO Mesoblast Ltd NTLA Intellia Therapeutics RGLS Regulus Therapeutics XLRN Acceleron Pharma

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score